Webinar:

Ulcerative Colitis : Current and Future Trends

Sponsored by: GlobalData

Focused on:

  • Ibd
  • Uc Treatment
  • Drug Forecast
  • Ulverative Colitis

Date: 22 May

Days to go: 2

Time: 4PM London/11AM New York

This expert presentation is exclusive only for GlobalData's clients. The recording and presentation will be available on the Intelligence Center. For any requests or questions about this presentation please contact kim.roz@globaldata.com

Inflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In UC, chronic inflammation affects the colon or large intestines, which are synonymous terms. UC usually manifests initially in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis).

The treatment of UC differs by location of the disease, severity, chronicity, prior and current treatments as well as hospitalization. UC therapy requires a lifetime of continuous treatment and monitoring for different states of activity within the disease. Currently, drugs with new mechanisms of action are on the horizon to add to the current treatment options, such as JAK inhibitors and S1P1 agonists. For the long-term management of UC, endoscopic remission, also known as mucosal healing, has recently become a significant aim for patients.

In this expert presentation Patrick Aiyes, Healthcare Analyst at GlobalData, will present the changing UC treatment landscape between 2016 and 2026, drawing on insights from GlobalData’s upcoming report, Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026. The current treatment options and drug pipeline for UC will be covered, including a discussion on GlobalData's sales forecast for the UC market. The webinar will include insights from KOLs covering the most important unmet needs for UC, as well as the opportunities which are likely to remain by the end of the forecast period. Dr. Lakshmi Dharmarajan, Associate Director of Immunology at GlobalData, will moderate a Q&A session following the presentation.

Presented by

Patrick Aiyes,

Healthcare Analyst

Patrick Aiyes, MEng, is an analyst in the Immunology therapy team at GlobalData in London. He is currently responsible for providing expert insight and detailed reports in the Immunology space with an emphasis on disease market and therapy forecasting. Previously Patrick was involved in improving clients' experience with the dataset for clinical trials and scoping company pipelines for new information for the Clinical Trials and Investigators database. Prior to GlobalData, Patrick worked in the life science staffing industry for just over a year where he managed accounts of companies such as Pfizer, Alere, and Ferring. Patrick graduated from City University London with a MEng in Biomedical Engineering with a First Class Honours.

Lakshmi Dharmarajan,

Associate Director of Immunology

Lakshmi Dharmarajan, PhD, PPM, is the Associate Director of the Immunology team at GlobalData in Boston, where she manages the Immunology syndicated market research portfolio. Her team provides actionable insights to clients over a wide range of diseases including autoimmune, dermatological, gastrointestinal and niche orphan disorders. Lakshmi has over 6 years of experience in pharma market research and consulting, having worked with various clients across the healthcare industry. Lakshmi holds a Ph.D. in Biochemistry from Virginia Tech as well as a Masters in bioscience management from Keck Graduate Institute.

Key Learning Objectives

  • Learn how GlobalData expects the UC market landscape to change between 2016 and 2026 across the 7 major markets (US, France, Germany, Italy, Spain, the UK and Japan)
  • Gain insight on the late-stage pipeline for UC, including which products GlobalData expects to succeed, and why.
  • Learn which unmet needs KOLs identified in the UC treatment landscape, and whether or not they are likely to be met by the current pipeline.
  • Identify which companies are set to be the major players in UC during the forecast period.

Audience

  • Senior Managers
  • Associate Directors
  • Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers